Implications for Practice
antibody reduced, tumor, pancreatic adenocarcinoma
PROLIFERATION, TUMOR, PANCREATIC ADENOCARCINOMA
Dysregulation of the hepatocyte growth factor (HGF)/c-Met signaling pathway can lead to aberrant cell proliferation, drug resistance, and promotion of cell migration and invasion. In pre-clinical pancreatic adenocarcinoma models, ficlatuzumab, an anti-HGF monoclonal antibody reduced tumor burden in combination with gemcitabine. In this multi-center, phase Ib dose escalation study, 2 dose cohorts of ficlatuzumab (10 and 20 mg/kg intravenously every 2 weeks) were administered with gemcitabine and 